Medical devices firm CytoSorbents Q2 revenue beats estimates

Cytosorbents

07/08/2025 21:17

Overview

CytoSorbents Q2 2025 revenue grows 9%, beating analyst expectations, per LSEG data

Net income for Q2 2025 reaches $1.9 mln, a turnaround from a loss last year

Adjusted loss per share meets analyst expectations, per LSEG data

Outlook

CytoSorbents aims for near breakeven by end of 2025

CytoSorbents focuses on improving gross margins and controlling costs

Company confident in resolving Health Canada regulatory issues

Result Drivers

GERMANY SALES - 22% year-over-year sales growth in Germany drove revenue increase

REORGANIZATION - Reorganization of German commercial team led to improved sales performance

COST MANAGEMENT - Focus on controlling costs and driving efficiencies to manage core business to near breakeven

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$9.62 mln
$9.23 mln (3 Analysts)
Q2 Adjusted EPS
Meet
-$0.05
-$0.05 (3 Analysts)
Q2 EPS
$0.03
Q2 Product Gross Margin
70.9%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Cytosorbents Corp is $4.00, about 77.5% above its August 6 closing price of $0.90

Press Release: ID:nPn9qCpWxa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)